Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis

Table 1 Characteristics of included studies

Ref.	Year	Patients assessed	KRAS wt	KRAS mut	Response criteria
1st line treatment
Maughan et al[11]	2011	1630	729	565	RECIST
Van Cutsem et al[12]	2011	1198	666	397	WHO
Bokemeyer et al[7]	2011	337	179	136	WHO
Douillard et al[13]	2010	1183	656	440	RECIST
Hecht et al[14]	2009	823	404	260	RECIST
Hecht et al[14]	2009	230	115	86	RECIST
Tol et al[15]	2009	755	314	206	RECIST
Tveit et al[16]	2012	566	303	195	RECIST
2nd line treatment
Peeters et al[17]	2010	1186	597	486	RECIST
Harbison et al[18]	2012	572	245	208	RECIST
Amado et al[19]	2008	463	243	184	RECIST

RECIST: Response Evaluation Criteria in Solid Tumor.

Table 2 Treatment protocols in included studies

Ref.	Study treatment protocol
1st line treatment
Maughan et al[11]	Ox 85 mg/m2 FA 350 mg/m2 5FU 400 mg/m2 bolus + 2400 mg/m2 infusion ± cetuximab
	Ox 130 mg/m2 Cap 2000 mg/m2± cetuximab
Van Cutsem et al[12]	Iri 180 mg/m2 FA 400 mg/m2 5FU 400 mg/m2 bolus + 2400 mg/m2 infusion ± cetuximab
Bokemeyer et al[7]	Ox 85 mg/m2 FA 400 mg/m2 5FU 400 mg/m2 bolus + 1200 mg/m2 infusion ± cetuximab
Douillard et al[13]	Ox 85 mg/m2 FA 400 mg/m2 5FU 400 mg/m2 bolus + 1200 mg/m2 infusion ± panitumumab
Hecht et al[14]	Ox/FA/5FU/Bev
Hecht et al[14]	Iri/FA/5FU/Bev
Tol et al[15]	Ox/Cap/Bev
Tveit et al[16]	Ox 85 mg/m2 FA 120 mg/m2 5FU 1000 mg/m2 bolus ± cetuximab
2nd line treatment
Peeters et al[17]	Iri 180 mg/m2 FA 400 mg/m2 5FU 400 mg/m2 bolus + 2400 mg/m2 infusion ± panitumumab
Harbison et al[18]	BSC ± cetuximab
Amado et al[19]	BSC ± panitumumab

Ox: Oxaliplatin; FA: Folinic acid; 5FU: 5-fluourouracil; Cap: Capecitabine; Iri: Irinotecan; Bev: Bevacizumab; BSC: Best supportive care.